In this article, we will discuss Ramucirumab (23). So, let’s get started.
Clinical Trials Experience (3)
Across clinical trials of Ramucirumab administered as a single agent, clinically relevant adverse reactions (including
Grade ≥3) reported in Ramucirumab-treated patients included proteinuria, gastrointestinal perforation, and infusion-related reactions. In Study 1, according to laboratory assessment, 8% of Ramucirumab-treated patients developed proteinuria versus
3% of placebo-treated patients. Two patients discontinued Ramucirumab due to proteinuria. The rate of gastrointestinal
perforation in Study 1 was 0.8% and the rate of infusion-related reactions was 0.4%.